Skip to main content

Choosing a Long Acting Injectable (LAI) Anti-Psychotic: Patient & Prescriber Perspective on Treatment

Enrollment is Closed

About this course

Multiple relapses characterize the course of disease in most patients with schizophrenia. Long-acting injectable (LAI) antipsychotics can help improve adherence to schizophrenia therapy to minimize relapse episodes. In a dinner symposium sponsored by Lundbeck, Professor Nagesh Pai of the University of Wollongong, Australia, discussed the benefits of LAI antipsychotics with focus on aripiprazole once-monthly (Abilify Maintena®) and reviewed clinical considerations for their use in schizophrenia.

1 CME Point Available (Category 3A)

  • Complete the videos and quiz to qualify for 1 CME Point (Category 3A).
  • A certificate will be provided upon successful completion. Please use the information on the certificate to claim your points via SMC website.
  • Doctors who have attended the face-to-face meeting will not be eligible for additional CME points for completing this module.

Our Speaker

Professor Pai is currently a Professor & Academic Leader of Psychiatry at the University of Wollongong and Senior Clinical Academic, Psychogeriatric services at the Illawarra Shoalhaven Local Health District.

  • Adjunct Professor of Psychiatry & Medical Education at Manipal University
  • Visiting Professor of Psychiatry at SRM University in India

Find out more about Professor Pai in the module.

Organized by

An educational talk supported by Lundbeck